Alle Studien
RekrutierungTherapeutische Erkundung (Phase II)Interventionell

OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TERM EFFECTIVENESS OF ORALLY ADMINISTERED EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADULT OR LATE-ONSET JUVENILE TYPE C NIEMANN-PICK DISEASE WITH COGNITIVE IMPAIRMENT

Niemann-Pick disease type C is a rare genetic condition that affects how the body handles fats like cholesterol. Over time, this can lead to difficulties with memory, thinking, movement, and swallowing. This clinical trial is testing a daily tablet called efavirenz in adults with the condition. Efavirenz is an established medicine being investigated to see if it can help break down fats in the brain and slow down cognitive decline. Because this is an 'open-label' study, all participants will receive the active medicine rather than a dummy pill (placebo). Over 52 weeks, doctors will closely monitor participants' safety, liver health, and thinking abilities using regular memory tests, blood checks, and brain scans. The goal is to see if efavirenz is safe and whether it helps preserve brain function over the long term.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Erkundung (Phase II)
Sponsor
Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Einschreibeziel
16
Starten
16. Mai 2024

Worum geht es in dieser Studie?

Niemann-Pick disease type C is a rare inherited condition that causes fatty substances, including cholesterol, to build up inside the body's cells. While it can affect organs like the liver and spleen, it also impacts the brain. Over time, people with the condition may notice problems with their balance, speech, swallowing, and thinking skills such as memory and concentration.

Efavirenz is a tablet that has been used for many years to treat viral infections. Scientists recently discovered that it may also switch on a natural enzyme in the brain that helps break down excess cholesterol. Researchers hope that by clearing this build-up, the medicine might protect brain cells and slow down the mental decline caused by Niemann-Pick disease.

This study is an 'extension study', designed to monitor participants over a full year (52 weeks). Doctors want to see how well the body tolerates taking efavirenz over a longer period, checking particularly on liver function and everyday wellbeing. They also want to measure whether memory, attention, and daily thinking skills remain stable rather than worsening.

By taking part, participants provide vital information that could lead to new treatment options for a rare condition that currently has very few available therapies.

Wichtige Erkenntnisse

  • Tests whether the oral drug efavirenz is safe and helps thinking skills in Niemann-Pick disease type C.
  • Open to adults aged 18 and older with adult-onset or late-onset juvenile forms of the condition.
  • This is an open-label trial, meaning all participants receive the active medicine.
  • Treatment and monitoring last for 52 weeks (one year).
  • Involves regular safety checks, liver tests, thinking puzzles, and brain scans.

Wer könnte berechtigt sein?

This study is open to adults aged 18 and older who have been diagnosed with adult-onset or late-onset juvenile Niemann-Pick disease type C. Participants must also be experiencing some mild or moderate changes in their memory, concentration, or problem-solving skills.

Both men and women can join. Because the trial involves regular visits and detailed assessments, participants will need to be able to travel to the study clinic and complete memory tests, either on their own or with support from a family member or carer.

Some people may not be able to take part—for example, if they have severe liver problems or are taking other medicines that might react badly with efavirenz. The study team will review each person's full medical history and current medications before confirming if they are suitable.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you aged 18 or older?
  2. Have you been diagnosed with adult or late-onset juvenile Niemann-Pick disease type C?
  3. Have you noticed changes in your memory, thinking, or concentration?
  4. Are you able and willing to take a daily oral tablet for 52 weeks?
  5. Can you attend regular hospital appointments for check-ups and scans?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

Taking part involves taking efavirenz tablets by mouth every day for at least 52 weeks (one year). You will need to visit the study hospital regularly for check-ups.

During clinic visits, the medical team will carry out several assessments. These include answering memory and thinking puzzles, having eye movement checks, and having physical examinations to test balance and swallowing. You will also have routine blood tests to check your liver health, an ultrasound scan of your tummy, and brain scans (such as MRI and PET scans) to see how your brain is functioning. In some cases, a small sample of fluid from around the spine (a lumbar puncture) may be collected to check brain chemical levels.

The trial team will support you throughout the year and monitor your health closely at every step.

Potenzielle Risiken und Vorteile

Taking part may help slow down changes in your thinking and memory, though this cannot be guaranteed. The study will also help doctors learn more about how to treat Niemann-Pick disease type C in the future. However, all medicines can cause side effects. Efavirenz can sometimes affect liver function, sleep, or mood, which is why regular safety checks are carried out. Tests like blood samples or lumbar punctures may also cause temporary soreness. Joining the trial is entirely voluntary, and you are free to stop taking part at any time without it affecting your usual NHS care.

Standorte (1)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Spanien

Häufige Fragen

Was ist eine 'Open-Label'-Studie?

An open-label study means both you and your trial doctors know exactly what medicine you are receiving. There are no dummy pills (placebos) in this trial; every participant receives efavirenz.

Will this medicine cure Niemann-Pick disease type C?

No, efavirenz is not a cure. The study is testing whether the drug can help manage symptoms and slow down the decline in memory and thinking abilities.

How often will I need to visit the hospital?

You will need to attend several clinic visits over the course of the 52-week study. The trial team will give you a clear schedule of visits before you decide to take part.

Can I bring a family member or carer with me?

Yes. Having a carer or loved one accompany you to appointments is strongly encouraged, as they can help with travel and support you through the memory assessments.

What happens if I want to leave the study early?

You are completely free to leave the study at any point. You do not have to give a reason, and your regular medical care will continue as normal.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TER… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.